Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Protagonist Therapeutics IncPTGX | $147.75 | Strong Buy | $182.00 | +23.18% | a day ago | |
Analyst RankingTop 5% #274 out of 5500 analysts Average Return+14.14% Win Rate59%122 out of 208 Risk vs RewardPoor Good Analyst ColorCitigroup's Geoff Meacham raised their price target on Protagonist Therapeutics (NASDAQ: PTGX) by 4% from $175 to $182 on 2026/08/31. The analyst maintained their Strong Buy rating on the stock. Meacham contextualized their price target hike on Protagonist Therapeutics by calling the FDA's approval of Mimrylo a "major de-risking" event for the name because the drug's label is broad. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.